Tolebrutinib Slows Disability in Non-Relapsing Secondary Progressive MS
Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's tyrosine kinase (BTK) inhibitor met the study's primary endpoint of delaying time to onset of 6-month confirmed disability progression (CDP),